Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Tango Therapeutics, Inc.NASDAQ: TNGX

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $24.91M rose 275.9% year over year, ahead of the +109.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 47.4% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.

Context

  • Stock-based compensation amounted to 42.4% of revenue in FY2025, down 26.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +275.9% holds above the trailing-twelve-month pace of +109.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$24.91M+47.4% QoQ
Last fiscal yearDec 2025
$26.43M-8.5% YoY
LTMSep 2026
$58.58M+109.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+275.9%——
1 year-8.5%——
3-year CAGR+22.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
26.43M USD
Year-over-year change
-8.5%
4-year CAGR
+35.5%

Stock-Based Compensation vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 stock-based compensation of $58.58M is the 2nd largest of the 11 companies compared; the peer median is $26.04M.
  • Its year-over-year change of +109.9% is the highest of 11, against a peer median of -1.1%.
  • Over three fiscal years its annual growth of +22.9% compares with a peer median of +10.5%.
TNGX Competitors Peer median
Stock-Based Compensation for TNGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$151.77M +56.3%+56.0%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$58.58M +109.9%+22.9%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$50.41M +30.4%+58.3%22.4%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$48.31M -34.7%+3.6%466.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M +8.7%+10.5%5.8%
ERASErasca, Inc.LTM Sep 2026$35.82M +41.1%+7.4%—
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M -43.8%-14.0%46.7%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M -11.0%+88.9%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M -60.8%-22.0%60.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
Peer median (excluding TNGX) $26.04M-1.1%+10.5%26.1%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
Deferred Income Tax00000
Stock-Based Compensation7.83M14.23M19.08M28.9M26.43M
Change in Working Capital(11.35M)(18.49M)(37.97M)(31.75M)(67.2M)
Accounts Receivables002M00
Inventory00000
Accounts Payables1.23M1.1M(1.71M)(1.18M)(825K)
Other Working Capital(12.58M)(19.59M)(38.26M)(30.56M)(66.37M)
Other Non-Cash Items1.32M1.75M234K(849K)1.2M
Operating Cash Flow(59.53M)(109.08M)(117.98M)(131.5M)(138.89M)
Capital Expenditures(1.84M)(7.69M)(1.53M)(754K)(1.05M)
Acquisitions (Net)00000
Purchases of Investments(372.36M)(208.5M)(310.57M)(240.89M)(264.46M)
Sales of Investments190.76M242.6M353.53M327.77M224.64M
Other Investing Activities00000
Investing Cash Flow(183.43M)26.4M41.43M86.13M(40.87M)
Debt Repayment342.11M0000
Common Stock Issued0080.02M41.72M222.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(14.78M)1.62M2.39M5.94M(36K)
Financing Cash Flow357.33M1.62M82.41M47.66M222.5M
Effect of Forex Changes00000
Net Change in Cash114.36M(81.07M)5.85M2.29M42.75M
Free Cash Flow(61.36M)(116.77M)(119.51M)(132.26M)(139.93M)

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.